Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

5.78USD
27 Sep 2016
Change (% chg)

$0.15 (+2.66%)
Prev Close
$5.63
Open
$5.63
Day's High
$5.78
Day's Low
$5.57
Volume
3,106,375
Avg. Vol
3,235,959
52-wk High
$7.15
52-wk Low
$2.50

SGYP.O

Chart for SGYP.O

About

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $1,010.29
Shares Outstanding(Mil.): 179.45
Dividend: --
Yield (%): --

Financials

  SGYP.O Industry Sector
P/E (TTM): -- 42.41 36.20
EPS (TTM): -1.24 -- --
ROI: -114.17 -0.33 13.87
ROE: -1,211.38 -3.14 14.78

BRIEF-Synergy Pharma Q2 net loss $38.6 million

* Synergy pharmaceuticals reports second quarter 2016 financial results and business update

Aug 08 2016

BRIEF-Synergy Pharma updates on FDA review clinical development program

* Provides update on ongoing FDA review Of Plecanatide CIC NDA and IBS-C clinical development program

Jul 15 2016

BRIEF-Synergy Pharmaceuticals reports Q1 loss per share $0.51

* Synergy Pharmaceuticals reports first quarter 2016 financial results and business update

May 10 2016

BRIEF-Synergy Pharmaceuticals closes $89.8 mln stock offering

* Synergy Pharmaceuticals Inc. announces closing of $89.8 million registered direct offering of common stock Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 09 2016

BRIEF-Synergy Pharma announces $89.8 mln registered direct offering of common stock

* Synergy pharmaceuticals inc. Announces $89.8 million registered direct offering of common stock

May 05 2016

BRIEF-Synergy pharmaceuticals announces resignation of CFO

* Synergy Pharmaceuticals announces resignation of chief financial officer

Apr 27 2016

BRIEF-Synergy Pharmaceuticals CEO Gary Jacob's 2015 total compensation $4.2 mln - SEC filing

* Says CEO Gary Jacob's 2015 total compensation was $4.2 million versus $3.1 million in 2014 - SEC filing Source text http://1.usa.gov/1TiKxWI Further company coverage:

Apr 20 2016

BRIEF-Synergy pharmaceuticals says FDA set Jan 29, 2017 as PDUFA for constipation drug

* Synergy pharmaceuticals announces acceptance of new drug application for plecanatide, a novel uroguanylin analog, in chronic idiopathic constipation

Apr 19 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.